Australia's Integral Diagnostics rises on Citi's upgrade to 'Buy' rating

Integral Diagnostics

06/03/2025 02:41

** Shares of Integral Diagnostics IDX.AX rise 4.7% to A$2.25

** Citi upgrades healthcare facilities provider to 'Buy' from 'Neutral,' keeps PT unchanged at A$2.70

** Brokerage forecasts higher revenue and margins for IDX in FY26, buoyed by partial MRI de-regulation, potential lung cancer screening contract, and benefits from Capitol Health merger

** Stock rose 5.1% earlier in the session

** 13 analysts rate the stock "buy" or higher and 1 "hold"; their mean PT is A$3.13 – LSEG

** Including session's gains, stock trims YTD decline to 22.3%

 (Reporting by Kumar Tanishk in Bengaluru)

 ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))